Squarepoint
TERN icon

Squarepoint’s Terns Pharmaceuticals TERN Stock Holding History

Squarepoint’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-275,350
Closed -$14.5M – 4972
2026
Q1 		$14.5M Buy
275,350
+250,183
+994% +$10.3M 0.02% 877
2025
Q4 		$1.02M Buy
25,167
+12,433
+98% +$287K ﹤0.01% 2589
2025
Q3 		$95.6K Sell
12,734
-75,104
-86% -$480K ﹤0.01% 4119
2025
Q2 		$328K Buy
87,838
+1,110
+1% +$3.47K ﹤0.01% 3620
2025
Q1 		$239K Buy
86,728
+73,603
+561% +$301K ﹤0.01% 3902
2024
Q4 		$72.7K Sell
13,125
-40,393
-75% -$274K ﹤0.01% 4768
2024
Q3 		$446K Buy
+53,518
New +$440K ﹤0.01% 3185
2024
Q2 		– Sell
-71,361
Closed -$468K – 4644
2024
Q1 		$468K Buy
+71,361
New +$466K ﹤0.01% 3089
2023
Q3 		– Sell
-15,871
Closed -$139K – 4244
2023
Q2 		$139K Buy
15,871
+2,946
+23% +$34.3K ﹤0.01% 3300
2023
Q1 		$153K Buy
+12,925
New +$124K ﹤0.01% 2884

Other funds holding TERN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Squarepoint's TERN Position: Q2 2026 in Review

Squarepoint sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 275,350 shares — an estimated $14.5M sold.

Squarepoint first reported a position in TERN in Q1 2023 and held it in 10 quarters. The position peaked at $14.5M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • Squarepoint reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 275,350 Terns Pharmaceuticals shares in Q2 2026, an estimated $14.5M.
  • Squarepoint first reported a position in Terns Pharmaceuticals in Q1 2023 and held it in 10 quarters.
  • Squarepoint's Terns Pharmaceuticals position peaked at $14.5M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.